ID   SH3K1_HUMAN             Reviewed;         665 AA.
AC   Q96B97; B7Z1D5; Q5JPT4; Q5JPT5; Q8IWX6; Q8IX98; Q96RN4; Q9NYR0;
DT   23-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-MAY-2003, sequence version 2.
DT   28-JUN-2023, entry version 199.
DE   RecName: Full=SH3 domain-containing kinase-binding protein 1;
DE   AltName: Full=CD2-binding protein 3;
DE            Short=CD2BP3;
DE   AltName: Full=Cbl-interacting protein of 85 kDa;
DE   AltName: Full=Human Src family kinase-binding protein 1;
DE            Short=HSB-1;
GN   Name=SH3KBP1; Synonyms=CIN85;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CBL.
RX   PubMed=10679202; DOI=10.1006/bbrc.2000.2147;
RA   Take H., Watanabe S., Takeda K., Yu Z.-X., Iwata N., Kajigaya S.;
RT   "Cloning and characterization of a novel adaptor protein, CIN85, that
RT   interacts with c-Cbl.";
RL   Biochem. Biophys. Res. Commun. 268:321-328(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=T-cell;
RX   PubMed=12618476; DOI=10.1093/intimm/dxg032;
RA   Tibaldi E.V., Reinherz E.L.;
RT   "CD2BP3, CIN85 and the structurally related adaptor protein CMS bind to the
RT   same CD2 cytoplasmic segment but elicit divergent functional activities.";
RL   Int. Immunol. 15:313-329(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adrenal cortex, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 262-665, AND VARIANT LEU-382.
RX   PubMed=11474197; DOI=10.1159/000056966;
RA   Narita T., Amano F., Yoshizaki K., Nishimoto N., Nishimura T., Tajima T.,
RA   Namiki H., Taniyama T.;
RT   "Assignment of SH3KBP1 to human chromosome band Xp22.1-->p21.3 by in situ
RT   hybridization.";
RL   Cytogenet. Cell Genet. 93:133-134(2001).
RN   [7]
RP   INTERACTION WITH BLNK; CRK; BCAR1; PIK3R3; GRB2 AND SOS1, AND
RP   SELF-ASSOCIATION.
RX   PubMed=11071869; DOI=10.1006/bbrc.2000.3760;
RA   Watanabe S., Take H., Takeda K., Yu Z.X., Iwata N., Kajigaya S.;
RT   "Characterization of the CIN85 adaptor protein and identification of
RT   components involved in CIN85 complexes.";
RL   Biochem. Biophys. Res. Commun. 278:167-174(2000).
RN   [8]
RP   INTERACTION WITH CBLB AND ENDOPHILINS, LACK OF INTERACTION WITH CBLC,
RP   FUNCTION IN RECEPTOR INTERNALIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12177062; DOI=10.1074/jbc.m205535200;
RA   Szymkiewicz I., Kowanetz K., Soubeyran P., Dinarina A., Lipkowitz S.,
RA   Dikic I.;
RT   "CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine
RT   kinases.";
RL   J. Biol. Chem. 277:39666-39672(2002).
RN   [9]
RP   FUNCTION IN RECEPTOR INTERNALIZATION, INTERACTION WITH EGFR; SH3GL1;
RP   SH3GL2; SH3GL3 AND CBL, AND SUBCELLULAR LOCATION.
RX   PubMed=11894095; DOI=10.1038/416183a;
RA   Soubeyran P., Kowanetz K., Szymkiewicz I., Langdon W.Y., Dikic I.;
RT   "Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF
RT   receptors.";
RL   Nature 416:183-187(2002).
RN   [10]
RP   FUNCTION IN RECEPTOR INTERNALIZATION, AND INTERACTION WITH SH3GL1; SH3GL2;
RP   SH3GL3; CBL AND MET.
RX   PubMed=11894096; DOI=10.1038/416187a;
RA   Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N.,
RA   Giordano S.;
RT   "The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation
RT   of c-Met.";
RL   Nature 416:187-190(2002).
RN   [11]
RP   UBIQUITINATION BY CBL AND CBLB.
RX   PubMed=12218189; DOI=10.1073/pnas.192462299;
RA   Haglund K., Shimokawa N., Szymkiewicz I., Dikic I.;
RT   "Cbl-directed monoubiquitination of CIN85 is involved in regulation of
RT   ligand-induced degradation of EGF receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12191-12196(2002).
RN   [12]
RP   INTERACTION WITH DAB2, AND IDENTIFICATION IN A COMPLEX WITH DAB2 AND
RP   CLATHRIN.
RX   PubMed=14596919; DOI=10.1016/s0014-5793(03)01111-6;
RA   Kowanetz K., Terzic J., Dikic I.;
RT   "Dab2 links CIN85 with clathrin-mediated receptor internalization.";
RL   FEBS Lett. 554:81-87(2003).
RN   [13]
RP   FUNCTION IN CELL ADHESION, AND INTERACTION WITH PDCD6IP; PTK2/FAK1 AND
RP   PTK2B/PYK2.
RX   PubMed=12771190; DOI=10.1242/jcs.00522;
RA   Schmidt M.H., Chen B., Randazzo L.M., Boegler O.;
RT   "SETA/CIN85/Ruk and its binding partner AIP1 associate with diverse
RT   cytoskeletal elements, including FAKs, and modulate cell adhesion.";
RL   J. Cell Sci. 116:2845-2855(2003).
RN   [14]
RP   INTERACTION WITH CD2 AND F-ACTIN CAPPING PROTEIN.
RX   PubMed=12690097; DOI=10.1074/jbc.m302540200;
RA   Hutchings N.J., Clarkson N., Chalkley R., Barclay A.N., Brown M.H.;
RT   "Linking the T cell surface protein CD2 to the actin-capping protein CAPZ
RT   via CMS and CIN85.";
RL   J. Biol. Chem. 278:22396-22403(2003).
RN   [15]
RP   FUNCTION IN RECEPTOR INTERNALIZATION.
RX   PubMed=12734385; DOI=10.1073/pnas.1031790100;
RA   Schmidt M.H., Furnari F.B., Cavenee W.K., Bogler O.;
RT   "Epidermal growth factor receptor signaling intensity determines
RT   intracellular protein interactions, ubiquitination, and internalization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6505-6510(2003).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [17]
RP   FUNCTION IN RECEPTOR INTERNALIZATION, INTERACTION WITH ASAP1; ARAP3; HIP1R;
RP   SYNJ2; INPP5D; STAP1 AND EGFR, IDENTIFICATION IN A COMPLEX WITH ASAP1 AND
RP   ARAP3, AND SUBCELLULAR LOCATION.
RX   PubMed=15090612; DOI=10.1091/mbc.e03-09-0683;
RA   Kowanetz K., Husnjak K., Holler D., Kowanetz M., Soubeyran P., Hirsch D.,
RA   Schmidt M.H., Pavelic K., De Camilli P., Randazzo P.A., Dikic I.;
RT   "CIN85 associates with multiple effectors controlling intracellular
RT   trafficking of epidermal growth factor receptors.";
RL   Mol. Biol. Cell 15:3155-3166(2004).
RN   [18]
RP   INTERACTION WITH PDCD6IP; EGFR; CBL AND CBLB.
RX   PubMed=15456872; DOI=10.1128/mcb.24.20.8981-8993.2004;
RA   Schmidt M.H., Hoeller D., Yu J., Furnari F.B., Cavenee W.K., Dikic I.,
RA   Bogler O.;
RT   "Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by
RT   the Cbl-SETA/CIN85 complex.";
RL   Mol. Cell. Biol. 24:8981-8993(2004).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH MAP3K4.
RX   PubMed=16256071; DOI=10.1016/j.bbrc.2005.10.032;
RA   Aissouni Y., Zapart G., Iovanna J.L., Dikic I., Soubeyran P.;
RT   "CIN85 regulates the ability of MEKK4 to activate the p38 MAP kinase
RT   pathway.";
RL   Biochem. Biophys. Res. Commun. 338:808-814(2005).
RN   [20]
RP   INTERACTION WITH SPRY2.
RX   PubMed=15962011; DOI=10.1038/sj.embor.7400453;
RA   Haglund K., Schmidt M.H., Wong E.S., Guy G.R., Dikic I.;
RT   "Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth
RT   factor receptor downregulation.";
RL   EMBO Rep. 6:635-641(2005).
RN   [21]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH SRC; LCK; LYN; FGR; FYN; HCK;
RP   TRADD; BIRC2; TRAF1; TRAF2 AND TNFR1.
RX   PubMed=15707590; DOI=10.1016/j.yexcr.2004.11.005;
RA   Narita T., Nishimura T., Yoshizaki K., Taniyama T.;
RT   "CIN85 associates with TNF receptor 1 via Src and modulates TNF-alpha-
RT   induced apoptosis.";
RL   Exp. Cell Res. 304:256-264(2005).
RN   [22]
RP   FUNCTION IN RECEPTOR INTERNALIZATION.
RX   PubMed=16177060; DOI=10.4049/jimmunol.175.7.4208;
RA   Molfetta R., Belleudi F., Peruzzi G., Morrone S., Leone L., Dikic I.,
RA   Piccoli M., Frati L., Torrisi M.R., Santoni A., Paolini R.;
RT   "CIN85 regulates the ligand-dependent endocytosis of the IgE receptor: a
RT   new molecular mechanism to dampen mast cell function.";
RL   J. Immunol. 175:4208-4216(2005).
RN   [23]
RP   INTERACTION WITH ARHGAP17.
RX   PubMed=16678097; DOI=10.1016/j.cell.2006.02.045;
RA   Wells C.D., Fawcett J.P., Traweger A., Yamanaka Y., Goudreault M.,
RA   Elder K., Kulkarni S., Gish G., Virag C., Lim C., Colwill K.,
RA   Starostine A., Metalnikov P., Pawson T.;
RT   "A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity
RT   proteins in epithelial cells.";
RL   Cell 125:535-548(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   INTERACTION WITH DDN AND MAGI2, AND SUBCELLULAR LOCATION.
RX   PubMed=16751601; DOI=10.1093/jb/mvj105;
RA   Kawata A., Iida J., Ikeda M., Sato Y., Mori H., Kansaku A., Sumita K.,
RA   Fujiwara N., Rokukawa C., Hamano M., Hirabayashi S., Hata Y.;
RT   "CIN85 is localized at synapses and forms a complex with S-SCAM via
RT   dendrin.";
RL   J. Biochem. 139:931-939(2006).
RN   [26]
RP   INTERACTION WITH MVB12A.
RX   PubMed=16895919; DOI=10.1074/jbc.m605693200;
RA   Konishi H., Tashiro K., Murata Y., Nabeshi H., Yamauchi E., Taniguchi H.;
RT   "CFBP is a novel tyrosine-phosphorylated protein that might function as a
RT   regulator of CIN85/CD2AP.";
RL   J. Biol. Chem. 281:28919-28931(2006).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; SER-436; SER-509;
RP   SER-511; SER-521 AND SER-587, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   INTERACTION WITH MAP3K4 AND ZFP36, AND SUBCELLULAR LOCATION.
RX   PubMed=20221403; DOI=10.1371/journal.pone.0009588;
RA   Kedar V.P., Darby M.K., Williams J.G., Blackshear P.J.;
RT   "Phosphorylation of human tristetraprolin in response to its interaction
RT   with the Cbl interacting protein CIN85.";
RL   PLoS ONE 5:E9588-E9588(2010).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230; SER-436 AND SER-587, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   FUNCTION.
RX   PubMed=21834987; DOI=10.1186/1741-7007-9-54;
RA   Bai S.W., Herrera-Abreu M.T., Rohn J.L., Racine V., Tajadura V.,
RA   Suryavanshi N., Bechtel S., Wiemann S., Baum B., Ridley A.J.;
RT   "Identification and characterization of a set of conserved and new
RT   regulators of cytoskeletal organisation, cell morphology and migration.";
RL   BMC Biol. 9:54-54(2011).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230; THR-254; SER-436 AND
RP   SER-587, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183; SER-509 AND SER-511, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   FUNCTION, AND INVOLVEMENT IN IMD61.
RX   PubMed=29636373; DOI=10.1084/jem.20170534;
RA   Keller B., Shoukier M., Schulz K., Bhatt A., Heine I., Strohmeier V.,
RA   Speckmann C., Engels N., Warnatz K., Wienands J.;
RT   "Germline deletion of CIN85 in humans with X chromosome-linked antibody
RT   deficiency.";
RL   J. Exp. Med. 215:1327-1336(2018).
RN   [38]
RP   INTERACTION WITH CHIKUNGUNYA VIRUS NON-STRUCTURAL PROTEIN 3 (MICROBIAL
RP   INFECTION).
RX   PubMed=31493651; DOI=10.1016/j.virol.2019.08.022;
RA   Agback P., Dominguez F., Pustovalova Y., Lukash T., Shiliaev N.,
RA   Orekhov V.Y., Frolov I., Agback T., Frolova E.I.;
RT   "Structural characterization and biological function of bivalent binding of
RT   CD2AP to intrinsically disordered domain of chikungunya virus nsP3
RT   protein.";
RL   Virology 537:130-142(2019).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-58 IN COMPLEX WITH CBLB.
RX   PubMed=16228008; DOI=10.1038/nsmb1000;
RA   Jozic D., Cardenes N., Deribe Y.L., Moncalian G., Hoeller D., Groemping Y.,
RA   Dikic I., Rittinger K., Bravo J.;
RT   "Cbl promotes clustering of endocytic adaptor proteins.";
RL   Nat. Struct. Mol. Biol. 12:972-979(2005).
CC   -!- FUNCTION: Adapter protein involved in regulating diverse signal
CC       transduction pathways. Involved in the regulation of endocytosis and
CC       lysosomal degradation of ligand-induced receptor tyrosine kinases,
CC       including EGFR and MET/hepatocyte growth factor receptor, through an
CC       association with CBL and endophilins. The association with CBL, and
CC       thus the receptor internalization, may be inhibited by an interaction
CC       with PDCD6IP and/or SPRY2. Involved in regulation of ligand-dependent
CC       endocytosis of the IgE receptor. Attenuates phosphatidylinositol 3-
CC       kinase activity by interaction with its regulatory subunit (By
CC       similarity). May be involved in regulation of cell adhesion; promotes
CC       the interaction between TTK2B and PDCD6IP. May be involved in the
CC       regulation of cellular stress response via the MAPK pathways through
CC       its interaction with MAP3K4. Is involved in modulation of tumor
CC       necrosis factor mediated apoptosis. Plays a role in the regulation of
CC       cell morphology and cytoskeletal organization. Required in the control
CC       of cell shape and migration. Has an essential role in the stimulation
CC       of B cell activation (PubMed:29636373). {ECO:0000250,
CC       ECO:0000269|PubMed:11894095, ECO:0000269|PubMed:11894096,
CC       ECO:0000269|PubMed:12177062, ECO:0000269|PubMed:12734385,
CC       ECO:0000269|PubMed:12771190, ECO:0000269|PubMed:15090612,
CC       ECO:0000269|PubMed:15707590, ECO:0000269|PubMed:16177060,
CC       ECO:0000269|PubMed:16256071, ECO:0000269|PubMed:21834987,
CC       ECO:0000269|PubMed:29636373}.
CC   -!- SUBUNIT: Can self-associate and form homotetramers. Interacts with CD2,
CC       F-actin capping protein, PIK3R3, GRB2, EGFR, MET, BLNK, MAP3K4,
CC       PDCD6IP, SPRY2, ARHGAP17, ARHGAP27, MAGI2, CRK, BCAR1, SOS1, ASAP1,
CC       ARAP3, HIP1R, SYNJ2, INPP5D and STAP1. Interacts with CBL and CBLB, but
CC       does not interact with CBLC. Two molecules of SH3KBP1 seem to bind
CC       through their respective SH3 1 domain to one molecule of CBLB. The
CC       interaction with CBL or CBLB and EGFR is increased upon EGF
CC       stimulation. The interaction with CBL is attenuated by PDCD6IP.
CC       Interacts through its proline-rich region with the SH3 domain of
CC       endophilins SH3GL1, SH3GL2 and SH3GL3. The SH3KBP1-endophilin complex
CC       seems to associate with a complex containing the phosphorylated
CC       receptor (EGFR or MET) and phosphorylated CBL. Probably associates with
CC       ASAP1 and phosphorylated EGFR. Probably part of a complex consisting of
CC       at least SH3KBP1, ASAP1 and ARAP3. Interacts with focal adhesion
CC       kinases PTK2/FAK1 and PTK2B/PYK2, probably as a dimer. Interacts with
CC       DAB2 and probably associates with chathrin through its interaction with
CC       DAB2. Part of a complex consisting of SH3KBP1, DAB2, and clathrin heavy
CC       chain. DAB2 and clathrin dissociate from SH3KBP1 following growth
CC       factor treatment, enabling interaction with CBL. Interacts with DDN and
CC       probably associates with MAGI2 through its interaction with DDN.
CC       Interacts with the SH3 domains of SRC tyrosine-protein kinases SRC,
CC       LCK, LYN, FGR, FYN and HCK. Interacts with TRADD, BIRC2, TRAF1, TRAF2
CC       and TNFR1, and the association with a TNFR1-associated complex upon
CC       stimulation with TNF-alpha seems to be mediated by SRC. Interacts (via
CC       SH3 domains) with SHKBP1 (via PXXXPR motifs) (By similarity).
CC       Interaction with CBL is abolished in the presence of SHKBP1 (By
CC       similarity). Interacts (via SH3 domains) with ZFP36 (via extreme C-
CC       terminal region) (PubMed:20221403). Interacts with MAP3K4; this
CC       interaction enhances the association with ZFP36 (PubMed:20221403).
CC       {ECO:0000250|UniProtKB:Q8R550, ECO:0000269|PubMed:10679202,
CC       ECO:0000269|PubMed:11071869, ECO:0000269|PubMed:11894095,
CC       ECO:0000269|PubMed:11894096, ECO:0000269|PubMed:12177062,
CC       ECO:0000269|PubMed:12690097, ECO:0000269|PubMed:12771190,
CC       ECO:0000269|PubMed:14596919, ECO:0000269|PubMed:15090612,
CC       ECO:0000269|PubMed:15456872, ECO:0000269|PubMed:15707590,
CC       ECO:0000269|PubMed:15962011, ECO:0000269|PubMed:16228008,
CC       ECO:0000269|PubMed:16256071, ECO:0000269|PubMed:16678097,
CC       ECO:0000269|PubMed:16751601, ECO:0000269|PubMed:16895919,
CC       ECO:0000269|PubMed:20221403}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via SH3 domains) with
CC       Chikungunya virus non-structural protein 3 (via C-terminus); this
CC       interaction plays a role in initiation of viral replication.
CC       {ECO:0000269|PubMed:31493651}.
CC   -!- INTERACTION:
CC       Q96B97; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-346595, EBI-11954519;
CC       Q96B97; Q8WWN8: ARAP3; NbExp=4; IntAct=EBI-346595, EBI-4402732;
CC       Q96B97; Q9ULH1: ASAP1; NbExp=11; IntAct=EBI-346595, EBI-346622;
CC       Q96B97; O43150: ASAP2; NbExp=3; IntAct=EBI-346595, EBI-310968;
CC       Q96B97; Q6PI77: BHLHB9; NbExp=5; IntAct=EBI-346595, EBI-11519926;
CC       Q96B97; P52907: CAPZA1; NbExp=5; IntAct=EBI-346595, EBI-355586;
CC       Q96B97; P22681: CBL; NbExp=20; IntAct=EBI-346595, EBI-518228;
CC       Q96B97; Q13191: CBLB; NbExp=22; IntAct=EBI-346595, EBI-744027;
CC       Q96B97; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-346595, EBI-10961624;
CC       Q96B97; A6NC98: CCDC88B; NbExp=3; IntAct=EBI-346595, EBI-347573;
CC       Q96B97; P06729: CD2; NbExp=3; IntAct=EBI-346595, EBI-3912464;
CC       Q96B97; Q9Y5K6: CD2AP; NbExp=4; IntAct=EBI-346595, EBI-298152;
CC       Q96B97; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-346595, EBI-3867333;
CC       Q96B97; O94850: DDN; NbExp=5; IntAct=EBI-346595, EBI-5240523;
CC       Q96B97; Q9ULE3-2: DENND2A; NbExp=3; IntAct=EBI-346595, EBI-13305669;
CC       Q96B97; P50570: DNM2; NbExp=5; IntAct=EBI-346595, EBI-346547;
CC       Q96B97; Q86UU5: GGN; NbExp=3; IntAct=EBI-346595, EBI-10259069;
CC       Q96B97; Q92835: INPP5D; NbExp=6; IntAct=EBI-346595, EBI-1380477;
CC       Q96B97; O60333-2: KIF1B; NbExp=3; IntAct=EBI-346595, EBI-10975473;
CC       Q96B97; Q5T749: KPRP; NbExp=5; IntAct=EBI-346595, EBI-10981970;
CC       Q96B97; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-346595, EBI-741037;
CC       Q96B97; Q9Y6R4: MAP3K4; NbExp=5; IntAct=EBI-346595, EBI-448104;
CC       Q96B97; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-346595, EBI-5461341;
CC       Q96B97; P07237: P4HB; NbExp=3; IntAct=EBI-346595, EBI-395883;
CC       Q96B97; P53803: POLR2K; NbExp=3; IntAct=EBI-346595, EBI-395357;
CC       Q96B97; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-346595, EBI-396669;
CC       Q96B97; P78314: SH3BP2; NbExp=8; IntAct=EBI-346595, EBI-727062;
CC       Q96B97; Q99962: SH3GL2; NbExp=2; IntAct=EBI-346595, EBI-77938;
CC       Q96B97; O43597: SPRY2; NbExp=2; IntAct=EBI-346595, EBI-742487;
CC       Q96B97; Q13501: SQSTM1; NbExp=4; IntAct=EBI-346595, EBI-307104;
CC       Q96B97; Q9ULZ2: STAP1; NbExp=5; IntAct=EBI-346595, EBI-6083058;
CC       Q96B97; O15056: SYNJ2; NbExp=5; IntAct=EBI-346595, EBI-310513;
CC       Q96B97; Q05BL1: TP53BP2; NbExp=3; IntAct=EBI-346595, EBI-11952721;
CC       Q96B97; P0CG48: UBC; NbExp=6; IntAct=EBI-346595, EBI-3390054;
CC       Q96B97; O76024: WFS1; NbExp=3; IntAct=EBI-346595, EBI-720609;
CC       Q96B97; O15156-2: ZBTB7B; NbExp=3; IntAct=EBI-346595, EBI-11522250;
CC       Q96B97; Q7Z783; NbExp=3; IntAct=EBI-346595, EBI-9088990;
CC       Q96B97; P98078: Dab2; Xeno; NbExp=9; IntAct=EBI-346595, EBI-1391846;
CC       Q96B97; P39052: Dnm2; Xeno; NbExp=4; IntAct=EBI-346595, EBI-349613;
CC       Q96B97; Q9JKY5: Hip1r; Xeno; NbExp=3; IntAct=EBI-346595, EBI-642457;
CC       Q96B97-1; Q13191-1: CBLB; NbExp=3; IntAct=EBI-7585212, EBI-15555129;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20221403}.
CC       Cytoplasm, cytoskeleton. Cytoplasmic vesicle membrane; Peripheral
CC       membrane protein. Synapse, synaptosome. Cell junction, focal adhesion
CC       {ECO:0000250}. Note=Localized in endocytic vesicles containing
CC       clustered receptors. Colocalizes with ASAP1 in vesicular structures.
CC       Colocalized with actin microfilaments and focal adhesions (By
CC       similarity). Colocalized with MAGI2 in synaptosomes. Translocation to
CC       EGFR containing vesicles upon EGF stimulation is inhibited in the
CC       presence of SH3KBP1 (By similarity). Colocalizes with ZFP36 in the
CC       cytoplasm (PubMed:20221403). {ECO:0000250|UniProtKB:Q8R550,
CC       ECO:0000269|PubMed:20221403}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96B97-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96B97-2; Sequence=VSP_007504;
CC       Name=3;
CC         IsoId=Q96B97-3; Sequence=VSP_044655, VSP_044656;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Also expressed in some
CC       cancer cell lines.
CC   -!- PTM: Monoubiquitinated by CBL and CBLB after EGF stimulation; probably
CC       on its C-terminus.
CC   -!- DISEASE: Immunodeficiency 61 (IMD61) [MIM:300310]: An X-linked
CC       recessive primary immunologic disorder characterized by recurrent
CC       infections due to impaired antibody production. Affected individuals
CC       have normal numbers of circulating B and T cells, but B cells have an
CC       intrinsic defect in antibody production. Disease severity is variable
CC       and onset is in early childhood. {ECO:0000269|PubMed:29636373}.
CC       Note=The disease may be caused by variants affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Interacts with CBL.
CC   -!- MISCELLANEOUS: [Isoform 2]: Interacts with CD2 cytoplasmic tail and
CC       does not interact with F-actin. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH50663.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF230904; AAF37854.1; -; mRNA.
DR   EMBL; AF542051; AAN77231.1; -; mRNA.
DR   EMBL; AK293234; BAH11470.1; -; mRNA.
DR   EMBL; AK293237; BAH11471.1; -; mRNA.
DR   EMBL; AL732423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL732327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL732325; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL732409; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL772197; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015806; AAH15806.1; -; mRNA.
DR   EMBL; BC050663; AAH50663.1; ALT_SEQ; mRNA.
DR   EMBL; AF329267; AAK95587.1; -; mRNA.
DR   EMBL; AF329268; AAO13348.1; -; mRNA.
DR   CCDS; CCDS14193.1; -. [Q96B97-1]
DR   CCDS; CCDS35213.1; -. [Q96B97-2]
DR   CCDS; CCDS55383.1; -. [Q96B97-3]
DR   PIR; JC7191; JC7191.
DR   RefSeq; NP_001019837.1; NM_001024666.2. [Q96B97-2]
DR   RefSeq; NP_001171889.1; NM_001184960.1. [Q96B97-3]
DR   RefSeq; NP_114098.1; NM_031892.2. [Q96B97-1]
DR   RefSeq; XP_016884958.1; XM_017029469.1.
DR   PDB; 2BZ8; X-ray; 2.00 A; A/B=1-58.
DR   PDB; 2K6D; NMR; -; A=267-328.
DR   PDB; 2K9G; NMR; -; A=262-333.
DR   PDB; 2N64; NMR; -; A/B/C=594-665.
DR   PDB; 2O2O; NMR; -; A=92-168.
DR   PDB; 2YDL; X-ray; 2.05 A; A=270-328.
DR   PDB; 5ABS; X-ray; 1.74 A; A=599-662.
DR   PDBsum; 2BZ8; -.
DR   PDBsum; 2K6D; -.
DR   PDBsum; 2K9G; -.
DR   PDBsum; 2N64; -.
DR   PDBsum; 2O2O; -.
DR   PDBsum; 2YDL; -.
DR   PDBsum; 5ABS; -.
DR   AlphaFoldDB; Q96B97; -.
DR   SMR; Q96B97; -.
DR   BioGRID; 119029; 371.
DR   CORUM; Q96B97; -.
DR   DIP; DIP-31803N; -.
DR   IntAct; Q96B97; 132.
DR   MINT; Q96B97; -.
DR   STRING; 9606.ENSP00000380921; -.
DR   GlyCosmos; Q96B97; 2 sites, 1 glycan.
DR   GlyGen; Q96B97; 11 sites, 1 O-linked glycan (11 sites).
DR   iPTMnet; Q96B97; -.
DR   MetOSite; Q96B97; -.
DR   PhosphoSitePlus; Q96B97; -.
DR   BioMuta; SH3KBP1; -.
DR   DMDM; 31077034; -.
DR   EPD; Q96B97; -.
DR   jPOST; Q96B97; -.
DR   MassIVE; Q96B97; -.
DR   MaxQB; Q96B97; -.
DR   PaxDb; Q96B97; -.
DR   PeptideAtlas; Q96B97; -.
DR   ProteomicsDB; 63029; -.
DR   ProteomicsDB; 76057; -. [Q96B97-1]
DR   ProteomicsDB; 76058; -. [Q96B97-2]
DR   Antibodypedia; 521; 233 antibodies from 32 providers.
DR   DNASU; 30011; -.
DR   Ensembl; ENST00000379698.8; ENSP00000369020.4; ENSG00000147010.19. [Q96B97-2]
DR   Ensembl; ENST00000379716.5; ENSP00000369039.1; ENSG00000147010.19. [Q96B97-3]
DR   Ensembl; ENST00000397821.8; ENSP00000380921.3; ENSG00000147010.19. [Q96B97-1]
DR   Ensembl; ENST00000699723.1; ENSP00000514545.1; ENSG00000147010.19. [Q96B97-2]
DR   GeneID; 30011; -.
DR   KEGG; hsa:30011; -.
DR   MANE-Select; ENST00000397821.8; ENSP00000380921.3; NM_031892.3; NP_114098.1.
DR   UCSC; uc004czl.4; human. [Q96B97-1]
DR   AGR; HGNC:13867; -.
DR   CTD; 30011; -.
DR   DisGeNET; 30011; -.
DR   GeneCards; SH3KBP1; -.
DR   HGNC; HGNC:13867; SH3KBP1.
DR   HPA; ENSG00000147010; Low tissue specificity.
DR   MalaCards; SH3KBP1; -.
DR   MIM; 300310; phenotype.
DR   MIM; 300374; gene.
DR   neXtProt; NX_Q96B97; -.
DR   OpenTargets; ENSG00000147010; -.
DR   PharmGKB; PA37822; -.
DR   VEuPathDB; HostDB:ENSG00000147010; -.
DR   eggNOG; KOG4348; Eukaryota.
DR   GeneTree; ENSGT00940000155886; -.
DR   HOGENOM; CLU_024255_1_0_1; -.
DR   InParanoid; Q96B97; -.
DR   OMA; PNSCHRS; -.
DR   OrthoDB; 2972088at2759; -.
DR   PhylomeDB; Q96B97; -.
DR   TreeFam; TF350191; -.
DR   PathwayCommons; Q96B97; -.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8866376; Reelin signalling pathway.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q96B97; -.
DR   SIGNOR; Q96B97; -.
DR   BioGRID-ORCS; 30011; 14 hits in 774 CRISPR screens.
DR   ChiTaRS; SH3KBP1; human.
DR   EvolutionaryTrace; Q96B97; -.
DR   GeneWiki; SH3KBP1; -.
DR   GenomeRNAi; 30011; -.
DR   Pharos; Q96B97; Tbio.
DR   PRO; PR:Q96B97; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q96B97; protein.
DR   Bgee; ENSG00000147010; Expressed in secondary oocyte and 188 other tissues.
DR   ExpressionAtlas; Q96B97; baseline and differential.
DR   Genevisible; Q96B97; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0007015; P:actin filament organization; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; NAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   CDD; cd12052; SH3_CIN85_1; 1.
DR   CDD; cd12055; SH3_CIN85_2; 1.
DR   CDD; cd12057; SH3_CIN85_3; 1.
DR   Gene3D; 2.30.30.40; SH3 Domains; 3.
DR   InterPro; IPR035770; CIN85_SH3_1.
DR   InterPro; IPR035771; CIN85_SH3_2.
DR   InterPro; IPR035772; CIN85_SH3_3.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR14167; SH3 DOMAIN-CONTAINING; 1.
DR   PANTHER; PTHR14167:SF6; SH3 DOMAIN-CONTAINING KINASE-BINDING PROTEIN 1; 1.
DR   Pfam; PF14604; SH3_9; 3.
DR   PRINTS; PR00499; P67PHOX.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00326; SH3; 3.
DR   SUPFAM; SSF50044; SH3-domain; 3.
DR   PROSITE; PS50002; SH3; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Cell junction; Coiled coil;
KW   Cytoplasm; Cytoplasmic vesicle; Cytoskeleton; Endocytosis;
KW   Host-virus interaction; Membrane; Phosphoprotein; Reference proteome;
KW   Repeat; SH3 domain; SH3-binding; Synapse; Synaptosome; Ubl conjugation.
FT   CHAIN           1..665
FT                   /note="SH3 domain-containing kinase-binding protein 1"
FT                   /id="PRO_0000097728"
FT   DOMAIN          1..58
FT                   /note="SH3 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          98..157
FT                   /note="SH3 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          267..328
FT                   /note="SH3 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REGION          159..200
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          328..444
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          467..610
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          602..664
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        162..200
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        353..390
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        470..507
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        509..531
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        532..548
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        569..587
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R550"
FT   MOD_RES         159
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R550"
FT   MOD_RES         183
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         230
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:19367720,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         254
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         436
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         509
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         587
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..54
FT                   /note="MVEAIVEFDYQAQHDDELTISVGEIITNIRKEDGGWWEGQINGRRGLFPDNF
FT                   VR -> MEVSAAKAPSAADLSEI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12618476,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_007504"
FT   VAR_SEQ         1..4
FT                   /note="MVEA -> MGEE (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044655"
FT   VAR_SEQ         5..242
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044656"
FT   VARIANT         382
FT                   /note="P -> L (in dbSNP:rs1310665369)"
FT                   /evidence="ECO:0000269|PubMed:11474197"
FT                   /id="VAR_015667"
FT   CONFLICT        288
FT                   /note="I -> T (in Ref. 3; BAH11471)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        426
FT                   /note="V -> A (in Ref. 3; BAH11471)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        570
FT                   /note="A -> V (in Ref. 5; AAH15806)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..8
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   STRAND          25..30
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   TURN            33..35
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   STRAND          36..41
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   STRAND          44..49
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   HELIX           50..52
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   STRAND          53..55
FT                   /evidence="ECO:0007829|PDB:2BZ8"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   STRAND          124..126
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   HELIX           130..132
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   STRAND          149..153
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   TURN            161..164
FT                   /evidence="ECO:0007829|PDB:2O2O"
FT   STRAND          270..276
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:2K6D"
FT   STRAND          293..299
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   STRAND          301..303
FT                   /evidence="ECO:0007829|PDB:2K9G"
FT   STRAND          306..311
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   STRAND          314..319
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:2YDL"
FT   HELIX           605..661
FT                   /evidence="ECO:0007829|PDB:5ABS"
SQ   SEQUENCE   665 AA;  73126 MW;  3BD350FCDB14BD4C CRC64;
     MVEAIVEFDY QAQHDDELTI SVGEIITNIR KEDGGWWEGQ INGRRGLFPD NFVREIKKEM
     KKDPLTNKAP EKPLHEVPSG NSLLSSETIL RTNKRGERRR RRCQVAFSYL PQNDDELELK
     VGDIIEVVGE VEEGWWEGVL NGKTGMFPSN FIKELSGESD ELGISQDEQL SKSSLRETTG
     SESDGGDSSS TKSEGANGTV ATAAIQPKKV KGVGFGDIFK DKPIKLRPRS IEVENDFLPV
     EKTIGKKLPA TTATPDSSKT EMDSRTKSKD YCKVIFPYEA QNDDELTIKE GDIVTLINKD
     CIDVGWWEGE LNGRRGVFPD NFVKLLPPDF EKEGNRPKKP PPPSAPVIKQ GAGTTERKHE
     IKKIPPERPE MLPNRTEEKE RPEREPKLDL QKPSVPAIPP KKPRPPKTNS LSRPGALPPR
     RPERPVGPLT HTRGDSPKID LAGSSLSGIL DKDLSDRSND IDLEGFDSVV SSTEKLSHPT
     TSRPKATGRR PPSQSLTSSS LSSPDIFDSP SPEEDKEEHI SLAHRGVDAS KKTSKTVTIS
     QVSDNKASLP PKPGTMAAGG GGPAPLSSAA PSPLSSSLGT AGHRANSPSL FGTEGKPKME
     PAASSQAAVE ELRTQVRELR SIIETMKDQQ KREIKQLLSE LDEEKKIRLR LQMEVNDIKK
     ALQSK
//
